Traws Pharma stock analysis
Want to see TRAW full AI Analyst Report?
Traws Pharma (TRAW) Stock Price & Analysis
TRAW Stock Chart & Stats
- Day’s Range
- $0.23 - $0.28
- 52-Week Range
- $0.22 - $3.23
- Previous Close
- $0.26
- Volume
- N/A
- Average Volume (3M)
- 199.43K
- Market Cap
- $3.59M
- Enterprise Value
- $8.37M
- Total Cash (Recent Filing)
- $3.13M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 0.79
- Next Earnings
- Mar 18, 2027 (Est.)
- EPS Estimate
- -0.11
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Ratutrelvir Clinical Progress
Phase 2a results show ratutrelvir achieved symptom resolution comparable to PAXLOVID, fewer treatment-related adverse events, and no rebound through Day 28. This supports a differentiated clinical profile, particularly for patients unable to use ritonavir, and advances the lead program toward later development.
TXM Formulation And Safety Progress
Comparable exposure and tolerability for the compressed TXM tablet support development of a more practical formulation, while the reported toxicology findings reduce a key preclinical hurdle. Together, these results strengthen the feasibility of the once-monthly influenza program and its continued advancement.
Flexible Development Funding
The equity facility gives Traws a defined source of capital for pipeline development, working capital, and general corporate needs over as long as 36 months. That flexibility can help maintain clinical execution despite limited internal cash generation and reduce dependence on immediate financing decisions.
Bears Say
Persistent Cash Burn
Consistently negative operating and free cash flow indicates that the company is not yet funding operations internally. The sharp 2025 deterioration increases reliance on external capital, constrains strategic flexibility, and could force financing activity before the pipeline produces commercial cash inflows.
Negative Equity And Weak Financial Flexibility
Negative equity means accumulated losses or write-downs have overwhelmed the capital base, even without reported debt. This weakens financial resilience, limits flexibility in funding research and development, and may make future capital raising more important as programs progress.
Unproven Core Earnings Quality
The apparent 2025 improvement in revenue and net income does not reflect stronger operating performance because EBITDA and EBIT remained deeply negative. This makes earnings difficult to sustain, leaves the business dependent on pipeline success, and limits confidence in near-term profitability.
Traws Pharma News
TRAW FAQ
What was Traws Pharma’s price range in the past 12 months?
What is Traws Pharma’s market cap?
When is Traws Pharma’s upcoming earnings report date?
How were Traws Pharma’s earnings last quarter?
Is Traws Pharma overvalued?
Does Traws Pharma pay dividends?
What is Traws Pharma’s EPS estimate?
How many shares outstanding does Traws Pharma have?
What happened to Traws Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Traws Pharma?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Traws Pharma
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Iain D. Dukes
- Employees
- 7
- Website
- www.trawspharma.com
- Address
- 12 Penns Trail, Newtown, PA, 18940, US
Traws Pharma (TRAW) Earnings & Revenues
TRAW Earnings Call
Earnings Call SentimentNeutral
The call balanced meaningful scientific and financing progress against important regulatory and liquidity risks. Positives include a $60M contingent financing package, robust preclinical data, a next-gen tablet with ~30% higher exposure supporting once-monthly prophylaxis, an approved Australian bridging study and plans for a U.K. human challenge trial. Key negatives are a low year-end cash balance ($3.8M), an FDA clinical hold on the IND for toxicology concerns that could materially delay U.S. development, and dependence on milestone warrants and one-time accounting items for near-term financial stability. Overall, the update conveys cautious optimism but highlights significant execution and regulatory risks that must be resolved to fully realize the program’s potential.
View all TRAW earnings summariesTRAW Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |













